Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Sanguinetti, Changan Jiang, M. Curran, M. Keating (1995)
A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channelCell, 81
Sergio Bran, William Murray, Irl Hirsch, Jerry Palmer (1995)
Long QT syndrome during high-dose cisapride.Archives of internal medicine, 155 7
L. Carlsson, G. Amos, Birgit Andersson, L. Drews, G. Duker, Gunilla Wadstedt (1997)
Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?The Journal of pharmacology and experimental therapeutics, 282 1
S. Ahmad, S. Wolfe (1995)
Cisapride and torsades de pointesThe Lancet, 345
D. Fedida, B. Wible, Z. Wang, B. Fermini, F. Faust, S. Nattel, A. Brown (1993)
Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.Circulation research, 73 1
Peter Honig, Dale Wortham, K. Zamani, Dale Conner, J. Mullin, L. Cantilena (1993)
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.JAMA, 269 12
T. Colatsky, T. Argentieri (1994)
Potassium channel blockers as antiarrhythmic drugsDrug Development Research, 33
Randy Wymore, G. Gintant, R. Wymore, J. Dixon, D. Mckinnon, I. Cohen (1997)
Tissue and species distribution of mRNA for the IKr-like K+ channel, erg.Circulation research, 80 2
D. Wysowski, J. Bacsanyi (1996)
Cisapride and fatal arrhythmia.The New England journal of medicine, 335 4
D. Rampe, B. Wible, A. Brown, R. Dage (1993)
Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart.Molecular pharmacology, 44 6
M. Roy, R. Dumaine, A. Brown (1996)
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.Circulation, 94 4
R. Pettignano, Chambliss Cr, Edress Darsey, Michael Heard, Reese Clark (1996)
Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support.Critical care medicine, 24 7
L. Wiseman, D. Faulds (2012)
CisaprideDrugs, 47
François Puisieux, M. Adamantidis, B. Dumotier, B. Dupuis (1996)
Cisapride‐induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibresBritish Journal of Pharmacology, 117
M. Curran, I. Splawski, K. Timothy, G.Michael Vincen, E. Green, M. Keating (1995)
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndromeCell, 80
S. Olsson, I. Edwards (1992)
Tachycardia during cisapride treatment.British Medical Journal, 305
J. Ben-David, D. Zipes (1993)
Torsades de pointes and proarrhythmiaThe Lancet, 341
Cisapride (Propulsid) is a gastrointestinal prokinetic agent commonly used to treat nocturnal heartburn as well as a variety of other gastrointestinal disorders. The use of cisapride has been associated with acquired long QT syndrome and ventricular arrhythmias such as torsades de pointes which produces sudden cardiac death. These cardiotoxic effects can be due to blockade of one or more types of K+ channel currents in the human heart. For this reason we compared the effects of cisapride on two cloned human cardiac K+ channels, Kv1.5 and the human ether‐a‐go‐go‐related gene (HERG) stably transfected into mammalian cells. Using patch clamp electrophysiology, we found that cisapride was a potent inhibitor of HERG displaying an IC50 value of 44.5 nmol/l when tail currents at −40 mV were measured following a 2 s test depolarization to +20 mV. When HERG currents were measured at the end of prolonged (20 s) depolarizing steps to +20 mV, the apparent affinity of cisapride was increased and measured 6.70 nmol/l. The main effect of cisapride was to enhance the rate of HERG current decay thereby reducing current at the end of the voltage clamp pulse. Furthermore, the potency of cisapride for the HERG channel was similar to that observed for the class III antiarrhythmic agent dofetilide (IC50=15.3 nmol/l) and the nonsedating antihistamine terfenadine (IC50=56.0 nmol/l). In contrast to its effects on HERG, cisapride inhibited Kv1.5 channel currents weakly displaying an IC50 value of 21.2 μmol/l. It is concluded that cisapride displays specific, high affinity block of the human cardiac K+ channel HERG. It is likely that this interaction underlies the proarrhythmic effects of the drug observed under certain clinical settings.
Febs Letters – Wiley
Published: Nov 3, 1997
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.